All In Biotech

NDA 217933 · Btg Intl

Aurlumyn

Iloprost · Intravenous · Prostacycline

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Feb 13, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

80

19 Phase 3, 2 recruiting

FAERS reports

932

880 serious, 286 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 13, 2026.

AURLUMYN is a prostacyclin mimetic indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. Effectiveness was established in young, healthy adults who suffered frostbite at high altitudes ( 1.1 ). 1.1 Frostbite AURLUMYN is indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. Effectiveness was established in young, healthy adults who suffered frostbite at high altitudes.

Mechanism: Iloprost is a synthetic analog of prostacyclin PGI 2 . Iloprost is a vasodilator and inhibits platelet aggregation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 13, 2024 Original approval · Type 3 - New Dosage Form · priority review OrphanLetterLabelReview
1 products under this application
  • AURLUMYN · ILOPROST 100MCG/ML (100MCG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Iloprost" as an intervention, any sponsor and status, largest first.

All 80 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective122
  • death77
  • off label use77
  • dyspnoea71
  • condition aggravated66
  • right ventricular failure64
  • pulmonary arterial hypertension59
  • hypotension52
  • pulmonary hypertension41
  • headache38
  • pneumonia38
  • maternal exposure during pregnancy37

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20058
20064
200715
200815
200921
201024
201115
201213
201317
201424
201530
201633
201743
201876
201992
202087
202180
202240
202369
202465
2025104
202654

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 336 on PubMed

Sponsor: Btg Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.